Cardiac Arrhythmias in Dravet Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02415686|
Recruitment Status : Completed
First Posted : April 14, 2015
Last Update Posted : September 7, 2018
People with Dravet Syndrome (DS), a rare epilepsy syndrome, have a high risk of Sudden Unexpected Death in Epilepsy (SUDEP). Mouse models indicated that the responsible sodium channel mutation (SCN1A) not only alters cortical excitability but also increases the propensity to arrhythmias. Little is known yet about the prevalence of seizure-induced arrhythmias in human DS subjects.
To assess the prevalence of cardiac arrhythmias in DS and to compare the prevalence of cardiac arrhythmias between DS subjects and subjects with other types of epilepsy.
Subjects with Dravet syndrome and a known pathogenic SCN1A mutation, seizure frequency ≥ 1/week (all seizure types except for absences or myoclonias), age ≥ 6 years and no signs of self-harm. Each case will be matched to two historical controls (age +/- 5 years) from the EEG databases of the participating centres. Only those controls with two or more recorded seizures will be matched to the cases.
Main study parameters/endpoints:
Ictal asystole Ictal bradycardia Ictal QT-shortening/lengthening
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Participation does not carry risks. The sensor is wearable and miniaturised, thus minimising discomfort. If this nevertheless may occur, the study can be terminated. This study provides specific tools to investigate the seizure-related heart rate response. Subjects may thus benefit from participation by identification of otherwise unknown arrhythmias. The rationale of the study (the high SUDEP risk and the evidence in animal studies for arrhythmic cause of sudden death) specifically applies to DS, a rare epileptic syndrome including minors and incapacitated persons. The investigators believe that the lack of risks, the potential diagnostic benefit, the minimal intervention with novel and wearable sensors and the possibility to terminate the study in case of discomfort, justifies the study in this patient group.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||59 participants|
|Official Title:||Cardiac Arrhythmias in Dravet Syndrome: an Observational, International, Multicentre Study|
|Actual Study Start Date :||June 2015|
|Actual Primary Completion Date :||August 29, 2018|
|Actual Study Completion Date :||August 29, 2018|
- Ictal asystole (sinus arrest ≥ 3 s) or ictal bradycardia (< 2nd heart rate percentile for age) [ Time Frame: We will record heart rate patterns during seizures with miniaturized wearable EKG-monitors for 2 periods of 10 days ]
- Ictal QT lengthening or shortening [ Time Frame: We will record heart rate patterns during seizures with miniaturized wearable EKG-monitors for 2 periods of 10 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02415686
|Bonn, North Rhine-Westphalia, Germany, 53113|
|Stichting Epilepsie Instellingen Nederland (SEIN)|
|Heemstede, Achterweg 5, Netherlands, 2103 SW|
|Great Ormond Street Hospital|
|London, South East, United Kingdom, WC1N 3JH|
|Principal Investigator:||Roland Thijs, Dr.||Stichting Epilepsie Instellingen Nederland (S.E.I.N.)|